Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-11 20:24:19 ET
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST
Company Participants
Chad Fugure - Vice President of Investor Relations
Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director
Scott Smith - CFO, Executive VP & Member of Executive Board
Jay Wu - Executive VP & President of Ascendis US
Aimee Shu - Executive VP & Chief Medical Officer
...
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-4.42% G/L:
$230.9284 Last:
382,909 Volume:
$240 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
